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ABSTRACT OF THE THESIS 
The Mesendodermal Stage of Development is Sustained within a Novel Population of 
Human Neonatal Cardiovascular Progenitor Cells 
 
by 
Julia Kim 
Master of Science, Graduate Program in Biochemistry 
Loma Linda University, June 2017 
Dr. Mary Kearns-Jonker, Chairperson 
 
 
 The rise in mortality due to cardiovascular disease has increased the need to 
develop an efficient regenerative therapeutic for heart failure. Numerous cell-based 
therapies have been investigated for myocardial regeneration; however, an optimal 
progenitor has yet to be discovered. Identifying a resident cell population with enhanced 
ability to differentiate into multiple lineages would greatly contribute to the field of stem 
cell-based regenerative therapy. Evidence suggests that endogenous cardiovascular 
progenitor cells (CPCs) that have been isolated from the heart itself express ISL1, KDR, 
and MESP1, and are capable of differentiating into all major cardiac lineages. The earlier 
developmental stage at which endogenous CPCs reside may be associated with enhanced 
multipotency and differentiation capacity. A clonal population of human neonatal CPCs 
expressing markers of early cardiovascular development was therefore selected for 
analysis. Based upon recent reports of differentiation into osteoblasts by cells expressing 
ISL1, we performed differentiation of the selected neonatal CPC into cardiovascular 
lineages as well as the mesodermal derivative, osteoblasts. Gene expression analysis and 
flow cytometry demonstrated differentiation into both cardiovascular and osteoblast 
lineages. To further address the relationship between an earlier developmental stage and 
xi 
differentiation capability, we measured the expression of mesendodermal regulatory 
markers, and discovered that this population of progenitor cells may reside earlier in 
development than previously recognized. These results suggest that neonatal 
cardiovascular progenitors expressing transcripts of the mesendoderm persist within the 
newborn human heart, exhibit enhanced differentiation capacity into various mesodermal 
lineages, and can be expanded for further assessment of functional and regenerative 
ability
1 
CHAPTER ONE 
INTRODUCTION 
 
For the last fifteen years, cardiovascular disease has been the leading cause of 
death worldwide1. Heart failure is predominantly associated with the loss of 
cardiomyocyte number and function following myocardial infarction, leading to 
cardiomyocyte hypertrophy, pathological remodeling of the heart, and ultimately to 
cardiac dysfunction (Lam et al., 2009). The heart’s limited regenerative capacity has 
prompted the investigation of stem cell-based therapeutics for cardiac repair (Cyganek et 
al., 2013; Garbern et al., 2013; Karra et al., 2008). Among the myriad of stem cell 
populations that have been investigated, endogenous cardiac stem cells show great 
promise for the treatment of heart failure (Fuentes et al., 2013; Mayfield et al., 2014; 
Nadal-Ginard et al., 2014). However, the origins of these progenitor cells and the 
mechanisms governing lineage specification and differentiation have yet to be fully 
elucidated (Chong et al., 2014). A comprehensive understanding of the identity and 
differentiation capacity of endogenous CPCs would greatly advance the field of stem 
cell-based regenerative therapy. 
The heart has long been thought to originate from two bilateral heart fields during 
early gastrulation (Brand, 2003); whereby the first heart field (FHF) contributes to the 
formation of the left ventricle and atria, and the second heart field (SHF) contributes 
predominantly to the right ventricle, outflow tract, and parts of the atria (Bruneau, 2013). 
Recently, however, an alternative school of thought regarding the origin of the heart has 
                                                 
1 Available at: http://www.who.int/mediacentre/factsheets/fs310/en/ Accessed March 4, 2017. 
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developed. Several studies have provided key insight into population(s) of multipotent 
cardiovascular progenitors that exist during the early stages of embryonic development, 
suggesting that the heart may actually be derived from a single primordial precursor with 
the ability to differentiate into all cardiac lineages rather than two separate progenitor 
populations (Abu-Issa et al., 2004; Meilhac et al., 2004; Moorman et al., 2007). Emerging 
evidence of an inverse relationship between the developmental stage and regenerative 
capacity of cardiac progenitors supports the need to investigate endogenous 
cardiovascular cell populations that reside at early stages of development (Porrello et al., 
2011; Fuentes et al., 2013; Jaszczak et al., 2016).  
Although little is known regarding the molecular identity of a single primordial 
precursor, advances in cell fate-mapping techniques revealed that CPC populations may 
be found prior to formation of the primitive streak in the developing mouse embryo 
(Audo-Boucher et al., 2000). Various signaling molecules and transcription factors play 
critical roles in promoting differentiation of CPCs that are present during this “pre-
streak” stage. Expression of the molecular markers Mesp1, Brachyury (T), and Flk-1 
(also known as KDR in humans) have been suggested to mark a population of cardiogenic 
primordial cells during murine embryonic development that are capable of differentiating 
into functional cardiomyocytes, endothelial, and smooth muscle cells (Kattman et al., 
2006; Meilhac et al., 2014; Chiapparo et al., 2016; Liu et al., 2016). The temporal 
appearance of Brachyury and Mesp1 have been shown to regulate the specification of the 
primitive streak (Bondue et al., 2008). Furthermore, knock out studies in mice support 
evidence suggesting that Mesp1 and Flk-1 are required for proper differentiation into the 
cardiovascular lineage (Saga et al., 1999; Kitajima et al., 2000; Abunnaja et al., 2014).  
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Analogous studies on human embryonic stem cells (hESCs) have revealed that 
MESP1 and KDR are expressed in human CPCs and are essential for heart formation 
(Yang et al., 2008; Ardehali et al., 2013). Cardiovascular progenitors expressing MESP1 
contribute to both first and second heart field derivatives (Bondue et al., 2010; Lescroart 
et al., 2014), and MESP1-null hearts lead to abnormalities during heart morphogenesis, 
resulting in cardia bifida. (Saga et al., 1996; 1999). Piccini and colleagues published data 
demonstrating that MESP1 expression peaks at day 2 of hESC differentiation, thereby 
indicating early and temporal expression of MESP1 in cardiac development (Piccini et 
al., 2016). Den Hartogh and Passier investigated the differentiation events of 
cardiovascular development in a dual MESP1mCherry/w-NKX2-5eGFP/w reporter line 
generated from hESCs and reported the gene expression profile of MESP1-positive cells 
compared to that of MESP1-negative cells. Results from this study revealed that early 
cardiac genes were enriched during peak expression of MESP1 (Den Hartogh et al., 
2014). These results are consistent with earlier findings that MESP1 expression occurs at 
early stages of development and serves as a key regulator of cardiovascular 
differentiation. Identifying a population of CPCs with multipotential capability would 
provide access to an optimal cell source for regenerating vital organs such as the heart. 
There has been an increasing emphasis on understanding the molecular role of 
MESP1 and KDR in the context of cardiovascular development; and more specifically, 
their interactions with cardiac transcription factors, such as ISL1 (Solloway et al., 2003; 
Kattman et al., 2007). Interestingly, ISL1 has been reported to be co-expressed with 
MESP1 in a subset of early MESP1-expressing cells (Bondue et al., 2008 & 2011). The 
LIM-homeodomain transcription factor, ISLET1, plays a critical role in cardiovascular 
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development (Laugwitz et al., 2005; Moretti et al., 2006, Wu et al., 2006). ISL1 marks a 
population of CPCs capable of giving rise to all cardiac lineages (Moretti et al., 2006; Ma 
et al., 2008; Fonoudi et al., 2013), and Isl1-null hearts in mice fail to undergo looping 
morphogenesis and are completely devoid of major components of the heart, including 
the outflow tract, right ventricle, and parts of the atria (Cai et al., 2003). ISL1 expression 
is required for the survival, proliferation and migration of progenitor cells into the cardiac 
tube during heart development (Laugwitz et al., 2008). A recent report on the engraftment 
of human ISL1-CPC spheroids after myocardial infarction in murine hearts showed that 
mice treated with ISL1-CPC spheroids exhibited reduced infarct area, increased blood 
vessel formation, and increased left ventricular contractile function compared to control 
animals (Bartulos et al., 2016). These results indicate that an MESP1+/ISL1+ CPC 
population is capable of demonstrating multipotential capability and could serve as a 
promising candidate for stem cell-based regenerative therapeutics. 
The efficacy of regeneration by CPCs expressing markers that are prevalent at 
varying stages of development have been investigated in both murine and human hearts. 
Studies in rodent hearts revealed a developmental stage-dependent discrepancy, whereby 
cell sources expressing early developmental markers demonstrated greater increases in 
regenerative capability than cells expressing late-stage markers (Table 1). Furthermore, 
cardiovascular progenitors expressing early developmental markers such as KDR, 
PDGFR, and ISL1 demonstrated better functional outcomes as measured by fractional 
shortening and/or ejection fraction (Table 1). Comparable results were shown in both 
mouse and human hearts following myocardial infarction. Such findings support the 
concept that early cardiovascular stem cells are better candidates for stem cell-based 
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therapies than late-stage cardiovascular stem cells. Moreover, CPCs provide a promising 
cell source for regenerative therapies due to minimal risk for teratoma formation 
following engraftment of cardiomyocytes relative to hESCs (Ardehali et al., 2013; Shiba 
et al., 2012; Chong et al., 2014; Harman et al., 2016). 
 
Table 1. Animal and human studies of next-generation cell-based regenerative therapies. 
 
Abbreviations: FS, fractional shortening; LVEF, left ventriclular ejection fraction; 
LVED, left ventricle at end-diastole volume. 
 
 
 
Among the wide array of cell populations studied within the field of stem cell-
based therapy for heart repair, endogenous CPCs from neonatal sources are considered to 
be the most promising. Cardiomyocyte exchange has been shown to occur more often in 
early childhood with a gradual decline throughout life (Bergmann et al., 2015), and 
Study Dev Stage Cell source Clinical effects 
Rodent 
(Fernandes et al., 2015) 
Early KDR+/PDGFR+ hESC-derived CPCs +28% FS 
(at 28 days) 
Rodent 
(Li et al., 2017) 
Early Isl1+ CPCs +20% LVEF  
(at 28 days)  
Rodent 
(Tang et al.., 2010) 
Late c-Kit+/EGFP+ CPCs +4% FS 
+8% LVEF 
(at 35 days) 
Human 
(Menasché et al., 2015) 
Early Isl1+/SSEA-1+ hESC-derived CPCs +10% LVEF 
(at 3 months) 
Human: CADUCEUS 
(Makkar et al., 2012) 
Late c-Kit+ cardiospheres +2% LVEF 
(at 6 months)  
Human: SCIPIO 
(Bolli et al., 2011) 
Late c-Kit+ Adult CPCs +12.3 ± 2.1% 
LVEF 
(at 4 months) 
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compelling results on the functional recovery of the human neonatal heart have been 
reported by numerous case studies (Saker et al., 1997; Farooqi et al., 2012; Cesna et al., 
2013; Haubner et al., 2016). Recent analysis of the injury response of human cardiac 
organoids (hCOs) revealed that, following cyroinjury in vitro, hCOs resembled neonatal-
like human cardiac tissue and underwent functional recovery in the absence of fibrosis or 
hypertrophy (Voges et al., 2017). Furthermore, neonatal CPCs demonstrate enhanced 
capacity for regulatory processes critical for regeneration, including proliferation, 
migration, and invasion (Fuentes et al., 2013; Mollova et al., 2013). MicroRNA analysis 
of neonatal CPCs co-expressing ISL1 and c-KIT, a population that is the focus of work 
done in our laboratory, revealed significant upregulation of transcripts that promote cell 
invasion compared to adult CPCs, and distinct clonal populations of neonatal CPCs 
expressed moderate to high levels of the pre-cardiac mesoderm markers KDR and 
PDGFR (Fuentes et al., 2013). Thus, this neonatal ISL1+/c-KIT+ population expressing 
markers of early cardiac development could serve as a cell source similar to that of a 
single primordial precursor with enhanced efficacy for heart repair. 
Stem cells expressing ISL1 have been shown to be capable of differentiation into 
an osteoblastic phenotype (Eberhardt et al., 2006; Itzhaki-Alfia et al., 2009; Akiyama et 
al., 2014). MESP1 expressing cells can differentiate into mesodermal derivatives 
including skeletal muscle and bone (Chan et al., 2013; Bondue et al., 2011). Emerging 
evidence suggests that MESP1 plays an important regulatory role in development (Liu, 
2017). Moreover, studies show that cells at early stages of development adopt their fate 
by location (Meilhac et al., 2014). Understanding the molecular properties contributing to 
mutipotency, commitment, and differentiation in cells that express all of these early 
7 
transcription factors is therefore necessary to identify the specific population of neonatal 
CPCs that may serve as optimal candidates for cardiac repair.  
The hunt for an ultimate progenitor has begun. With the rise in mortality due to 
heart disease, there is a growing need to develop an efficient regenerative therapeutic. 
The field of stem cell-based therapy has performed extensive analyses on numerous cell 
populations with limited efficacy. Studies reveal that endogenous human neonatal CPCs 
possess greater potential as a source of cells to regenerate the heart compared to adult 
CPCs (Simpson et al., 2012; Fuentes et al., 2013). ISL1, MESP1, and KDR are expressed 
on CPCs that can differentiate efficiently into all cardiovascular lineages (Moretti et al., 
2006; Lescroart et al., 2014; Bulatovic et al., 2016). Furthermore, neonatal CPCs co-
expressing ISL1, MESP1, KDR, as well as c-KIT have been isolated in our laboratory and 
may represent a candidate with multipotential differentiation capability as well as 
enhanced regenerative function. Thus, the work proposed in my specific aims has been 
directed towards identifying whether or not this ISL1, MESP1, KDR, and c-KIT 
expressing clonal population of human neonatal CPCs isolated by our laboratory has 
multipotential differentiation capability. Results from these studies will determine the 
capability of these stem cells to differentiate into cardiac as well as osteoblast lineages. 
Additionally, findings from this study will provide innovative and essential information 
that will contribute to better functional outcomes in future stem-cell based therapeutic 
studies for patients with heart disease.  
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Ethics Statement/ Maintenance of CPCs 
The Institutional Review Board of Loma Linda University approved the protocol 
for the use of discarded tissue during cardiovascular surgery, without identifiable 
information, for this study with a waiver of informed consent. Cell isolation and 
expansion protocols were performed in previous studies for further use in the laboratory 
(Fuentes et al., 2013). In brief, discarded atrial cardiac tissue obtained during 
cardiovascular surgery of human neonates was cut into ~1mm3 segments and collagenase 
digested (Roche Applied Science, Indianapolis, IN) for 2 hours at 37C at a proportion of 
1:2.5 tissue volume vs. collagenase. This solution was passed through a 40m cell 
strainer (Smits et al., 2009) and resulting cells were cloned by limiting dilution at a 
concentration of 0.8 cells per well to create clonal populations. 
 
 
Neonatal CPC Culture and in vitro Differentiation 
 Neonatal CPCs were cultured in 6-well plates coated with 0.1% gelatin. Control 
cells were cultured in CPC growth medium and passaged using 0.25% trypsin solution 
upon reaching 80% confluency. Cardiomyocyte differentiation of cardiac progenitor cells 
was performed by treatment with 5-azacytidine, ascorbic acid, and TGF- in 
differentiation media for 14 days (Smits et al., 2009). In brief, CPC growth medium was 
exchanged for differentiation medium once cells reached >80% confluency. After 6-8 
hours of changing media, 5µM 5-azacytidine was added directly to the cells for three 
consecutive days with a media change on day 4. Six days after the start of the 
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cardiomyocyte differentiation assay, 1000x stock 10-4 M ascorbic acid and 1ng/mL TGF-
 were added to the medium. Following the first treatment, ascorbic acid was added 
every 2 days, and TGF- was added twice weekly either during media changes or directly 
to the cells. Cells were taken at day 14 for qRT-PCR analysis. Endothelial tube formation 
was performed by thawing concentrated Matrigel (Corning) overnight in a 4C 
refrigerator on ice. The next day, pipette tips were cooled in -20C for 30 minutes and 
used to plate 50µL of thawed matrigel in each well of a 96-well plate. Plated matrigel 
was allowed to harden in a CO2 incubator for 30-60 minutes and 20,000 cells were plated 
per well in 150µL EGM-2 + 10% FBS and incubated for an additional 5 hours. Cells 
were washed twice with PBS and 3.75µL Calcein AM was added to 1mL of EGM-2. The 
staining solution was added to each well and incubated for a final 30 minutes. Staining 
medium was replaced with fresh EGM-2 +10% serum prior to imaging endothelial tubes 
at the 4x objective using an EVOS imaging system (Arnaoutova et al., 2009). To induce 
osteogenic differentiation, cells were cultured in DMEM +10% FBS supplemented with 
50µM ascorbic acid, 10mM -glycerophosphate and 100nM dexamethasone. Medium 
was changed twice weekly for 16 days, and cells were analyzed for qRT-PCR and flow 
cytometry analysis for osteoblast markers, RUNX2, OPN, COL1A1, ALPL, and OCN, at 
days 7 and 14-16 (Jaiswal et al., 1997, Sottile et al., 2003) (Figure 1). 
 
Figure 1. Osteogenic differentiation by ascorbic acid, -glycerophosphate, and 
dexamethasone treatment. 
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RNA Extraction 
 RNAprotect (Qiagen, Valencia, CA) and TRIzol reagent (Life Technologies, 
Grand Island, NY) were used to store cells. RNA was extracted from cells in RNAprotect 
using the Qiagen RNeasy Kit. Cells were homogenized in TRIzol reagent and RNA was 
isolated as per the manufacturer’s instructions. First strand cDNA synthesis was 
performed from 2g total RNA using Superscript III Reverse Transcriptase (Invitrogen, 
Grand Island, NY). 
 
qRT-PCR Analysis 
Quantitative RT-PCR was performed on a BioRad iQ5 Cycler as previously 
described (Fuentes et al., 2013). PCR conditions were as follows: 94C for 10 minutes, 
followed by cycles of 15 seconds at 94C for denaturation, annealing for 60 seconds at 
56C, and extension for 30 seconds at 72C for a total of 40 cycles for most primer pairs. 
Human primer pairs were designed using NCBI Primer Blast as well as taken from 
previously published literature (Sottile et al., 2003). Fold changes were calculated using 
the ΔΔCt method (Schmittgen et al., 2008). A list of primers that were used for qRT-PCR 
analysis may be found in supplemental table 1 (Table S1). 
 
Flow Cytometry 
 Following induction, cells were trypsinized, fixed with 4% paraformaldehyde, and 
labeled with antibodies at concentrations recommended by the manufacturers. Cells for 
osteoblast detection were labeled with mouse anti-human Osteocalcin Alexa Fluor 488 
conjugated antibody (R&D Systems, MN). FACS analysis was performed on a 
11 
MACSquant analyzer (Miltenyi Biotec, Auburn, CA). Forward- and side-scatter gating 
was used to gate out any small particles and/or dead cells. FlowJo software (Ashland, 
OR) was used for quantification. 
 
Statistical Analysis 
Data were processed using Microsoft Excel and Graphpad Prism 7.02 and expressed as 
the mean  S.E.M. Data were tested for normality using the Sharpiro-Wilk normality test. 
Statistical significance was determined using a Student’s t test for qRT-PCR analysis. P-
values less than 0.05 were assumed to be significant. 
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CHAPTER THREE 
RESULTS 
 
Human Neonatal CPCs Express a Distinct Set of Early Developmental Markers 
 
Clonal populations of human neonatal cardiovascular progenitor cells co-
expressing ISL1 and c-Kit were previously isolated and characterized for further use in 
the laboratory (Fuentes et al., 2013). Phenotypic profiling revealed distinct populations of 
neonatal CPCs expressing pre-cardiac mesoderm markers ISL1, KDR, and PDGFRa 
(Fuentes et al., 2013). In order to investigate the developmental stage of the neonatal 
CPC co-expressing ISL1, MESP1, KDR, and c-KIT, we performed gene expression 
analysis on neonatal CPCs for molecular markers associated with the mesoderm.  
All neonatal CPC clones that were examined for this study expressed the 
pluripotency marker OCT4, as well as markers of the mesoderm and mesendoderm 
including brachyury (T) and goosecoid (GSC), respectively. One of the clonal 
populations of neonatal CPCs uniquely expressed demonstrable levels of MESP1, along 
with its mesendodermal precursor, EOMES (Figure 2). This clone presented a gene 
expression profile similar to that of a primitive cardiogenic cell population. Based upon 
expression of early molecular markers associated with the mesoderm and pre-cardiac 
mesoderm, we sought to assess the differentiation capacity of this MESP1+ neonatal CPC 
(Figure 3). Previous studies have shown ISL1+/c-KIT+ co-expressing neonatal CPCs can 
differentiate into cardiomyocyte and endothelial cells. Differentiation into the cardiac and 
osteoblast lineage was performed on this ISL1+, c-KIT+, KDR+, and MESP1+ clone to 
investigate the differentiation and multipotential capacity. 
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Figure 2. mRNA analysis of molecular markers associated with mesoderm, precardiac 
mesoderm, and cardiac progenitors. Relative mRNA expression of pluripotent marker, 
OCT4, mesoderm (T, MIXL1, GSC, EOMES) and pre-cardiac mesoderm (MESP1, KDR, 
PDGFRa) in the select ISL1+/c-KIT+/KDR+ and MESP1+ clone by RT-PCR and resolved 
using an agarose gel.  
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Figure 3. Summary of the stage-specific expression of molecular markers associated with 
cardiovascular development. Blue text signifies activation. Sharp arrows represent 
stimulatory effects; blunt arrows depict inhibitory effects. 
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Differentiation of an ISL1+/c-KIT+ and MESP1+ Neonatal CPC into the Cardiac 
Lineage 
Cardiomyocyte differentiation was performed in order to confirm the 
differentiation capacity of the ISL1+/c-KIT+/MESP1+/KDR+ neonatal CPC along the 
cardiovascular lineage. The cardiomyocyte differentiation protocol was adapted from a 
previous report involving treatment of human cardiomyocyte progenitor cells with 5-
azacytidine, TGF-, and ascorbic acid (Smits et al., 2009). In addition, an endothelial 
tube formation assay was conducted to assess endothelial cell differentiation. Formation 
of tubes has been shown to determine the capability of cells to differentiate along the 
endothelial cell lineage (Arnaoutova et al., 2009). Endothelial cells respond to 
proangiogenic signals and migrate rapidly to form capillary-like tubes when plated over 
Matrigel (DeCicco-Skinner et al., 2014).  
 The ISL1+/c-KIT+/KDR+ and MESP1+ clone was capable of differentiation into 
cardiomyocytes and endothelial cells. Cardiomyocyte differentiation was demonstrated 
by a significant induction of the cardiomyogenic-specific transcript, Troponin T (TNNT2) 
(Figure 4). Furthermore, the neonatal clone effectively formed tubes (Figure 5), 
indicating that these cells have endothelial differentiation capacity. Following tube 
network formation, cells were imaged and documented using an EVOS FL imaging 
system set at the 4x objective. 
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Figure 4. Differentiation of ISL1+/c-KIT+/MESP1+/KDR+ human neonatal CPC into 
cardiomyocytes. After 14 days of culture in differentiation medium, gene expression levels 
for Troponin T (TNNT2) were elevated in the neonatal CPC expressing markers of early 
cardiovascular development (N=3, run in triplicate P < 0.05). 
  
  Control 
 (TNNT2) 
  Treated 
  (TNNT2) 
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Figure 5. Tube formation by the ISL1+/c-KIT+/ KDR+ and MESP1+ neonatal CPC clone 
verifies differentiation along the endothelial cell lineage. Representative images of 
endothelial cell tube formation over Matrigel in a select neonatal CPC exhibiting early 
developmental characteristics.  Scale bar = 1000 m (N = 3). 
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A Neonatal CPC Co-Expressing ISL1, c-KIT, KDR and MESP1 Differentiates into a 
Mature Osteoblast Phenotype 
 In order to assess the differentiation capacity of the early ISL1+/c-
KIT+/MESP1+/KDR+ neonatal CPC clone into mesodermal derivatives, differentiation 
into the osteoblast lineage was performed. Neonatal CPCs were cultured in 6-well plates 
at 5 x 103 cells per well in DMEM/10% FBS with osteogenic supplements, 50uM 
ascorbic acid, 10mM -glycerophosphate and 100nM dexamethasone (Figure 6) (Bielby 
et al., 2004; Jaiswal et al., 1997; Sottile et al., 2003). Dexamethasone acts to induce the 
expression of the transcription factor, RUNX2, through a beta-catenin-mediated pathway, 
while ascorbic acid and -glycerophosphate have been shown to play roles 
predominantly in establishing the extracellular matrix by increasing collagen type 1 
secretion and serving as a phosphate source, respectively (Langenbach et al., 2013).  
 
 
 
Figure 6. Timeline of neonatal CPC differentiation into osteoblasts. Cells were expanded 
in 6-well plates for 7 to 14/16 days.  
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Osteogenic-specific molecular markers were analyzed by qRT-PCR following 7 
days of induction which revealed a significant increase in the expression of early markers 
of osteoblast differentiation (Figure 7). RUNX2, the most upstream transcription factor 
essential for osteoblast differentiation (Komori, 2017), was found to be significantly 
elevated (519-fold, P=0.01) following the initial induction period. Osteopontin (OPN), 
one of the non-collagenous extracellular structural proteins secreted in the bone, has been 
shown to behave bimodally, by which peak expression occurs during active proliferation, 
decreases post-proliferatively, and peaks once more at the onset of mineralization (Lian 
et al., 1995; Twine et al., 2014). Similar to these findings, OPN expression was 
significantly induced in the neonatal CPC at the initial proliferative stages of osteoblast 
differentiation (Figure 7A). Alkaline phosphatase (ALPL) and Collagen type 1 (COL1A1) 
are important components for establishing the mineralized matrix present in bone (Stein 
et al., 1993). Expression of both mineralization and extracellular matrix-related 
transcripts were induced following 7 days of differentiation in osteogenic supplemented 
media. OCN expression has been shown to occur at later stages of osteoblast 
development and is reflective of a mature osteoblast phenotype (Lian et al., 1995; Ducy 
et al., 1995; Huang et al., 2007). In order to confirm osteoblast lineage commitment, gene 
and protein expression analyses of OCN were performed following 14-16 days of 
osteoblast induction. The neonatal CPC demonstrated an increase in the expression of the 
late-stage osteoblast marker by both qRT-PCR (Figure 8) and flow cytometry (Figure 9), 
and therefore verified differentiation of the selected ISL1+/c-KIT+/KDR+ and MESP1+ 
neonatal CPC into a mature osteoblast phenotype. Differentiation into the osteoblast 
lineage thereby confirms mutlipotential differentiation capability of this early progenitor. 
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Figure 7. Neonatal CPC co-expressing ISL1, c-KIT, KDR, and MESP1 treated with 
osteogenic supplements for 7 days showed enhanced expression of osteogenic markers. 
(A) Representative gene expression analysis of early developmental markers OPN (P ≤ 
0.01), RUNX2 (P ≤ 0.01), COL1A1 (P ≤ 0.0001), and ALPL (P ≤ 0.0001) following 7 days 
of differentiation. (B) RUNX2 and COL1A1 expression was induced ~500 and ~900 fold, 
respectively. Abbreviations: OPN, Osteopontin; OCN, Osteocalcin; Runx2, Runt related 
transcription factor 2; Col1A1, Collagen Type 1; ALPL, Alkaline Phosphatase (N=3). 
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Figure 8. The ISL1+/c-KIT+/KDR+ and MESP1+ Neonatal CPC treated with osteogenic 
supplements for 14-16 days showed enhanced expression of late-stage osteoblast 
differentiation marker, osteocalcin. Expression of the transcript for osteocalcin (OCN) was 
induced at 14-16 days of osteoblast differentiation (N=3, P <0.05). 
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Figure 9. The ISL1+/c-KIT+/KDR+ and MESP1+ Neonatal CPC treated with osteogenic 
supplements for 14-16 days showed enhanced expression osteocalcin by flow cytometry 
(A) Forward and side scatter dot plot of untreated and treated CPCs. (B) Flow cytometry 
histogram of increased OCN expression. Positive staining is represented by the colored 
histogram, dotted histogram is representative of the isotype control (N=3). 
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CHAPTER FOUR 
DISCUSSION 
 
In the present study, we demonstrated that neonatal CPCs isolated from the 
human heart co-expressing MESP1, c-KIT, KDR, and ISL1 can be induced to differentiate 
into various mesodermal lineages, including cardiovascular and bone. Differentiation into 
the osteoblast lineage by neonatal cardiac progenitors expressing this array of early 
developmental markers demonstrated enhanced multipotential capability. Osteoblasts, the 
specialized mesenchymal cells that synthesize bone are, in addition to the cardiovascular 
lineage, one of the mesodermal derivatives regulated by the Wnt-signaling pathway 
(Bakre et al., 2007; Yavropoulou et al., 2007). A lineage tracing study in mice 
demonstrated that development of the heart and hindlimb may be regulated by a common 
pathway in Isl1-expressing progenitors (Yang et al., 2006). This early study supports the 
concept that Isl1 marks a subset of heart and hindlimb progenitors, and Isl1 may be 
upstream in common heart/hindlimb pathways (Yang et al., 2006). Similarly, human 
cardiac progenitor cells expressing ISL1 have been reported to differentiate into the 
osteoblast lineage, further demonstrating the multipotential capability of ISL1-expressing 
progenitor populations. However, the findings from this group did not demonstrate 
clonogenicity of progenitor cells, nor were the cell populations examined for co-
expression of early developmental markers such as MESP1 and/or KDR that have been 
reported in the current study. Furthermore, the cardiac progenitor cells investigated did 
not exhibit an overlap between c-KIT and ISL1 expression (Itzhaki-Alfia et al., 2009). 
Taken together, these findings support the novel concept that isolation of cells on the 
basis of ISL1 and c-KIT coexpression selects for a subpopulation of cardiac progenitors 
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with enhanced multipotential differentiation capacity, and that these cells may be 
sustained within the mesendodermal stage of development. 
The ISL1+/c-KIT+/MESP1+/KDR+ neonatal CPC expressed transcripts for 
modulators of the mesendoderm, such as GSC, MIXL1, and EOMES, and therefore may 
reside in a stage of development that is earlier than the pre-cardiac mesoderm. GSC is 
strongly expressed in cell populations identified as mesendodermal regulators during the 
formation of the anterior primitive streak (Blum et al., 1992; Tada et al., 2005), and 
furthermore has been shown to be expressed in a majority of ISL1+/c-KIT+ neonatal CPCs 
that were examined in the present study. The mesendoderm has been characterized as a 
diverging point of the mesoderm and definitive endoderm during hESC differentiation 
(Tada et al., 2005). Interestingly, MESP1 has been shown to be involved in the regulation 
of the mesendodermal stage of embryogenesis (Soibam et al., 2015). Soibam and 
colleagues identified early cell lineages regulated by MESP1, and found that MESP1 
targets mesendoderm modulating markers, giving rise to progenitors of the mesoderm 
and endoderm during gastrulation (Soibam et al., 2015). Several mesendoderm regulatory 
factors that are activated by MESP1 include EOMES, GATA4, GSC, T, and MIXL1, 
suggesting that this ISL1+/c-KIT+/MESP1+/KDR+ neonatal CPC resides within the 
mesendodermal stage of development.  
The bipotent mesendoderm has been established as a very early developmental 
stage in many species, including C. elegans, drosophila, xenopus, and zebrafish 
(Rodaway and Patient, 2001). Fate mapping experiments have demonstrated that 
definitive endoderm progenitors are specified in close proximity to cardiovascular 
progenitors (Costello et al., 2015). The close association between mesoderm and 
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endoderm formation within the primitive streak in addition to the co-expression of 
markers specific for mesoderm and endoderm precursors in early progenitor cells, 
supports evidence of a common bipotential progenitor population originating at the onset 
of gastrulation (Rodaway et al., 1999; Kimelman and Griffin, 2000). Moreover, these 
reports suggest that a population of progenitor cells within this region may be capable of 
differentiating into both mesodermal and endodermal lineages. Further research to define 
the differentiation and regenerative properties of neonatal CPCs is ongoing. 
The present study sought to identify a population of human neonatal CPCs with 
enhanced differentiation and multipotential capability for applications in stem cell-based 
regenerative therapy. Our findings demonstrate that the KDR+, MESP1+, ISl1+, and c-
KIT+ endogenous human neonatal CPC are associated with the early stages of embryonic 
development and preserves characteristics of the mesendoderm, with the potential for 
enhanced efficacy. Analysis of several ISL1+/c-KIT+ adult CPCs revealed expression of 
transcripts for GSC, suggesting that the clonal populations from both neonatal as well as 
adult sources co-expressing ISl1 and c-KIT sustain transcripts of the mesendoderm. These 
exciting results provide valuable information regarding the identity of a cardiovascular 
stem cell population that may be implemented as an optimal source for numerous stem 
cell-based regenerative therapies. Future studies will focus on determining the 
differentiation propensity of endogenous neonatal CPCs into the endodermal lineage to 
verify the functionality of the expressed mesendodermal transcripts. 
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Table S1. List of primers used to detect gene expression by qRT-PCR 
Amplicon 
Product 
Size 
Tm-
Fwd 
Tm-
Rev 
Forward and Reverse Sequence (5’-3’) 
ACTIN 130bp 63 62 
Fwd: TTTGAATGATGAGCCTTCGTCCCC 
Rev: GGTCTCAAGTCAGTGTACAGGTAAGC 
ALPL 543bp 62 59 
Fwd: GGGGGTGGCCGGAAATACAT 
Rev: GGGGGCCAGACCAAAGATAG 
BRACHYURY 568bp 67 66 
Fwd: ACTGGATGAAGGCTCCCGTCTCCTT 
Rev: CCAAGGCTGGACCAATTGTCATGGG 
C-KIT 105bp 63 62 
Fwd: ATTCCCAAGCCCATGAGTCCTTGA 
Rev: ACACGTGGAACACCAACATCCT 
COL1 461bp 57 59 
Fwd: GGACACAATGGATTGCAAGG 
Rev: TAACCACTGCTCCACTCTGG 
EOMES 381bp 59 59 
Fwd: TTGAAAAAGGGCAGAAAGGCG 
Rev: TTTGCAAAGCGCAGACGG 
GATA4 189bp 58 59 
Fwd: GACAATCTGGTTAGGGGAAGC 
Rev: ACACAATGCAAAACCCACGG 
GSC 158bp 60 59 
Fwd: AACGCGGAGAAGTGGAACAA 
Rev: AGCATCGTCTGTCTGTGCAA 
ISL1 202bp 59 56 
Fwd: CACAAGCGTCTCGGGATTGTGTTT 
Rev: AGTGGCAAGTCTTCCGACAA 
KDR 219bp 62 61 
Fwd: CCTCTACTCCAGTAAACCTGATTGGG 
Rev: TGTTCCCAGCATTTCACACTATGG 
MESP1 377bp 60 60 
Fwd: CGCTATATCGGCCACCTGTC 
Rev: GGCATCCAGGTCTCCAACAG 
MIXL1 501bp 57 60 
Fwd: TTTTCTCCCCTCTTCCAGGTA 
Rev: CGTCATTGACAAAGTGGCGG 
NKX2-5 111bp 57 61 
Fwd: CGCCGCTCCAGTTCATAG 
Rev: GGTGGAGCTGGAGAAGACAGA 
OCN/ 
BGLAP 
294bp 60 65 
Fwd: ATGAGAGCCCTCACACTCCTC 
Rev: GCCGTAGAAGCGCCGATAGGC 
OCT4/ 
POU5F1 
123bp 65 63 
Fwd: AACCTGGAGTTTGTGCCAGGGTTT 
Rev: TGAACTTCACCTTCCCTCCAACCA 
OPN/ 
SPP1 
355bp 55 56 
Fwd: CATCTCAGAAGCAGAATCTCC 
Rev: CCATAAACCACACTATCACCTC 
PDGFRA 496bp 62 61 
Fwd: GCGCAATCTGGACACTGGGA 
Rev: ATGGGGTACTGCCAGCTCAC 
RUNX2 460bp 60 59 
Fwd: CCTCAGTGATTTAGGGCGCA 
Rev: GGTGTGGTAGTGAGTGGTGG 
TGFB1 384bp 60 60 
Fwd: GGGCTACCATGCCAACTTCT 
Rev: GACACAGAGATCCGCAGTCC 
TNNT2 131bp 59 57 
Fwd: GTGGGAAGAGGCAGACTGAG 
Rev: ATAGATGCTCTGCCACAGC 
 
